Ewan Forrest

Dr. Ewan Forrest is an Honorary Professor at the University of Glasgow's School of Cardiovascular & Metabolic Health. His research focuses on liver diseases, particularly alcohol-related liver disease (ARLD), non-alcoholic fatty liver disease (NAFLD), and hepatocellular carcinoma (HCC). He has contributed to studies on diet's role in liver disease progression, antibiotic prophylaxis in cirrhosis, and healthcare access improvements via initiatives like SHARP. His work combines clinical trials, epidemiology, and translational research.

Research Interests: Dr. Forrest's primary areas include ARLD pathogenesis, NAFLD epidemiology, and clinical management strategies for liver diseases. He explores dietary influences on liver outcomes and evaluates interventions like minimum alcohol pricing. Recent studies also address liver biopsy quality and risk stratification for HCC surveillance.

Publications Trends: Over 55 publications span 1996–2025, emphasizing diet-liver disease interactions (e.g., Nature Communications, 2024), antibiotic prophylaxis protocols (Trials, 2022), and ARLD cancer associations (Annals of Hepatology, 2025). His work bridges basic science and clinical practice, often leveraging large cohorts like UK Biobank.

Collaborations: Involved in trials like ASEPTIC (SBP prevention) and ISAIAH (canakinumab in alcoholic hepatitis). Partnerships include NHS Scotland's SHARP initiative and collaborations with researchers in hepatology, nutrition, and epidemiology.

Future Work: Ongoing projects include diet-based interventions for NAFLD and optimizing liver disease management through policy and clinical guidelines.